会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER
    • 贝伐珠单抗联合治疗乳腺癌的血液生物标志物
    • EP3156800A1
    • 2017-04-19
    • EP16184951.8
    • 2011-07-18
    • F. Hoffmann-La Roche AG
    • DE HAAS, Sanne LysbetDELMAR, PaulFOERNZLER, DorotheeKLAUSE, UrsulaSCHERER, Stefan
    • G01N33/574
    • G01N33/6893A61K31/337A61K39/3955G01N33/57415G01N2333/475G01N2800/52
    • The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer, by adding bevacizumab (Avastin Ⓡ ) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin Ⓡ ) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer.
    • 本发明提供了用于改善患有乳腺癌,特别是局部晚期复发或转移性HER-2阴性乳腺癌的患者的化疗方案的治疗效果的方法,通过将化疗方案加入贝伐单抗(阿瓦斯汀) 相对于诊断患有乳腺癌的患者的对照水平,特别是局部晚期复发或转移性HER-2阴性乳腺癌的VEGFA,VEGFR2和PLGF中的一种或多种的表达水平,特别是血浆表达水平。 具体而言,本发明提供了改善治疗效果的方法,其中治疗效果是患者的无进展存活。 本发明进一步提供了评估患者对贝伐单抗(阿瓦斯汀)与化疗方案组合的敏感性或反应性的方法,其通过确定VEGFA中的一种或多种的表达水平,特别是血浆表达水平, VEGFR2和PLGF相对于诊断患有乳腺癌,特别是局部晚期,复发或转移性HER-2阴性乳腺癌的患者中的对照水平。